Hyperoxia  ||| S:0 E:10 ||| NNP
may  ||| S:10 E:14 ||| MD
be  ||| S:14 E:17 ||| VB
beneficial  ||| S:17 E:28 ||| JJ
The  ||| S:28 E:32 ||| DT
current  ||| S:32 E:40 ||| JJ
practice  ||| S:40 E:49 ||| NN
of  ||| S:49 E:52 ||| IN
mechanical  ||| S:52 E:63 ||| JJ
ventilation  ||| S:63 E:75 ||| NN
comprises  ||| S:75 E:85 ||| VBZ
the  ||| S:85 E:89 ||| DT
use  ||| S:89 E:93 ||| NN
of  ||| S:93 E:96 ||| IN
the  ||| S:96 E:100 ||| DT
least  ||| S:100 E:106 ||| JJS
inspiratory  ||| S:106 E:118 ||| CD
O2  ||| S:118 E:121 ||| CD
fraction  ||| S:121 E:130 ||| NN
associated  ||| S:130 E:141 ||| VBN
with  ||| S:141 E:146 ||| IN
an  ||| S:146 E:149 ||| DT
arterial  ||| S:149 E:158 ||| JJ
O2  ||| S:158 E:161 ||| CD
tension  ||| S:161 E:169 ||| NN
of  ||| S:169 E:172 ||| IN
55  ||| S:172 E:175 ||| CD
to  ||| S:175 E:178 ||| TO
80  ||| S:178 E:181 ||| CD
mm  ||| S:181 E:184 ||| JJ
Hg  ||| S:184 E:187 ||| NNP
or  ||| S:187 E:190 ||| CC
an  ||| S:190 E:193 ||| DT
arterial  ||| S:193 E:202 ||| JJ
hemoglobin  ||| S:202 E:213 ||| NN
O2  ||| S:213 E:216 ||| CD
saturation  ||| S:216 E:227 ||| NN
of  ||| S:227 E:230 ||| IN
88 ||| S:230 E:232 ||| CD
%  ||| S:232 E:234 ||| NN
to  ||| S:234 E:237 ||| TO
95 ||| S:237 E:239 ||| CD
% ||| S:239 E:240 ||| NN
.  ||| S:240 E:242 ||| .
Early  ||| S:242 E:248 ||| RB
goal-directed  ||| S:248 E:262 ||| JJ
therapy  ||| S:262 E:270 ||| NN
for  ||| S:270 E:274 ||| IN
septic  ||| S:274 E:281 ||| JJ
shock ||| S:281 E:286 ||| NN
,  ||| S:286 E:288 ||| ,
however ||| S:288 E:295 ||| RB
,  ||| S:295 E:297 ||| ,
attempts  ||| S:297 E:306 ||| VBZ
to  ||| S:306 E:309 ||| TO
balance  ||| S:309 E:317 ||| VB
O2  ||| S:317 E:320 ||| CD
delivery  ||| S:320 E:329 ||| NN
and  ||| S:329 E:333 ||| CC
demand  ||| S:333 E:340 ||| NN
by  ||| S:340 E:343 ||| IN
optimizing  ||| S:343 E:354 ||| JJ
cardiac  ||| S:354 E:362 ||| JJ
function  ||| S:362 E:371 ||| NN
and  ||| S:371 E:375 ||| CC
hemoglobin  ||| S:375 E:386 ||| JJ
concentration ||| S:386 E:399 ||| NN
,  ||| S:399 E:401 ||| ,
without  ||| S:401 E:409 ||| IN
making  ||| S:409 E:416 ||| VBG
use  ||| S:416 E:420 ||| NN
of  ||| S:420 E:423 ||| IN
hyperoxia ||| S:423 E:432 ||| NN
.  ||| S:432 E:434 ||| .
Clearly ||| S:434 E:441 ||| RB
,  ||| S:441 E:443 ||| ,
it  ||| S:443 E:446 ||| PRP
has  ||| S:446 E:450 ||| VBZ
been  ||| S:450 E:455 ||| VBN
well-established  ||| S:455 E:472 ||| JJ
for  ||| S:472 E:476 ||| IN
more  ||| S:476 E:481 ||| JJR
than  ||| S:481 E:486 ||| IN
a  ||| S:486 E:488 ||| DT
century  ||| S:488 E:496 ||| NN
that  ||| S:496 E:501 ||| IN
long-term  ||| S:501 E:511 ||| JJ
exposure  ||| S:511 E:520 ||| NN
to  ||| S:520 E:523 ||| TO
pure  ||| S:523 E:528 ||| JJ
O2  ||| S:528 E:531 ||| CD
results  ||| S:531 E:539 ||| NNS
in  ||| S:539 E:542 ||| IN
pulmonary  ||| S:542 E:552 ||| NN
and ||| S:552 E:555 ||| CC
,  ||| S:555 E:557 ||| ,
under  ||| S:557 E:563 ||| IN
hyperbaric  ||| S:563 E:574 ||| JJ
conditions ||| S:574 E:584 ||| NNS
,  ||| S:584 E:586 ||| ,
central  ||| S:586 E:594 ||| JJ
nervous  ||| S:594 E:602 ||| JJ
O2  ||| S:602 E:605 ||| CD
toxicity ||| S:605 E:613 ||| NN
.  ||| S:613 E:615 ||| .
Nevertheless ||| S:615 E:627 ||| RB
,  ||| S:627 E:629 ||| ,
several  ||| S:629 E:637 ||| JJ
arguments  ||| S:637 E:647 ||| NNS
support  ||| S:647 E:655 ||| VBP
the  ||| S:655 E:659 ||| DT
use  ||| S:659 E:663 ||| NN
of  ||| S:663 E:666 ||| IN
ventilation  ||| S:666 E:678 ||| NN
with  ||| S:678 E:683 ||| IN
100 ||| S:683 E:686 ||| CD
%  ||| S:686 E:688 ||| NN
O2  ||| S:688 E:691 ||| NN
as  ||| S:691 E:694 ||| IN
a  ||| S:694 E:696 ||| DT
supportive  ||| S:696 E:707 ||| JJ
measure  ||| S:707 E:715 ||| NN
during  ||| S:715 E:722 ||| IN
the  ||| S:722 E:726 ||| DT
first  ||| S:726 E:732 ||| JJ
12  ||| S:732 E:735 ||| CD
to  ||| S:735 E:738 ||| TO
24  ||| S:738 E:741 ||| CD
hrs  ||| S:741 E:745 ||| NN
of  ||| S:745 E:748 ||| IN
septic  ||| S:748 E:755 ||| JJ
shock ||| S:755 E:760 ||| NN
.  ||| S:760 E:762 ||| .
In  ||| S:762 E:765 ||| IN
contrast  ||| S:765 E:774 ||| NN
to  ||| S:774 E:777 ||| TO
patients  ||| S:777 E:786 ||| NNS
without  ||| S:786 E:794 ||| IN
lung  ||| S:794 E:799 ||| NN
disease  ||| S:799 E:807 ||| NN
undergoing  ||| S:807 E:818 ||| VBG
anesthesia ||| S:818 E:828 ||| NN
,  ||| S:828 E:830 ||| ,
ventilation  ||| S:830 E:842 ||| NN
with  ||| S:842 E:847 ||| IN
100 ||| S:847 E:850 ||| CD
%  ||| S:850 E:852 ||| NN
O2  ||| S:852 E:855 ||| NN
does  ||| S:855 E:860 ||| VBZ
not  ||| S:860 E:864 ||| RB
worsen  ||| S:864 E:871 ||| VB
intrapulmonary  ||| S:871 E:886 ||| JJ
shunt  ||| S:886 E:892 ||| NN
under  ||| S:892 E:898 ||| IN
conditions  ||| S:898 E:909 ||| NNS
of  ||| S:909 E:912 ||| IN
hyperinflammation ||| S:912 E:929 ||| NN
,  ||| S:929 E:931 ||| ,
particularly  ||| S:931 E:944 ||| RB
when  ||| S:944 E:949 ||| WRB
low  ||| S:949 E:953 ||| JJ
tidal  ||| S:953 E:959 ||| JJ
volume-high  ||| S:959 E:971 ||| JJ
positive  ||| S:971 E:980 ||| JJ
end-expiratory  ||| S:980 E:995 ||| JJ
pressure  ||| S:995 E:1004 ||| NN
ventilation  ||| S:1004 E:1016 ||| NN
is  ||| S:1016 E:1019 ||| VBZ
used ||| S:1019 E:1023 ||| VBN
.  ||| S:1023 E:1025 ||| .
In  ||| S:1025 E:1028 ||| IN
healthy  ||| S:1028 E:1036 ||| JJ
volunteers  ||| S:1036 E:1047 ||| NNS
and  ||| S:1047 E:1051 ||| CC
experimental  ||| S:1051 E:1064 ||| JJ
animals ||| S:1064 E:1071 ||| NNS
,  ||| S:1071 E:1073 ||| ,
exposure  ||| S:1073 E:1082 ||| NN
to  ||| S:1082 E:1085 ||| TO
hyperoxia  ||| S:1085 E:1095 ||| NNS
may  ||| S:1095 E:1099 ||| MD
cause  ||| S:1099 E:1105 ||| VB
pulmonary  ||| S:1105 E:1115 ||| JJ
inflammation ||| S:1115 E:1127 ||| NN
,  ||| S:1127 E:1129 ||| ,
enhanced  ||| S:1129 E:1138 ||| VBN
oxidative  ||| S:1138 E:1148 ||| JJ
stress ||| S:1148 E:1154 ||| NN
,  ||| S:1154 E:1156 ||| ,
and  ||| S:1156 E:1160 ||| CC
tissue  ||| S:1160 E:1167 ||| NN
apoptosis ||| S:1167 E:1176 ||| NN
.  ||| S:1176 E:1178 ||| .
This ||| S:1178 E:1182 ||| DT
,  ||| S:1182 E:1184 ||| ,
however ||| S:1184 E:1191 ||| RB
,  ||| S:1191 E:1193 ||| ,
requires  ||| S:1193 E:1202 ||| VBZ
long-term  ||| S:1202 E:1212 ||| JJ
exposure  ||| S:1212 E:1221 ||| NN
or  ||| S:1221 E:1224 ||| CC
injurious  ||| S:1224 E:1234 ||| JJ
tidal  ||| S:1234 E:1240 ||| JJ
volumes ||| S:1240 E:1247 ||| NNS
.  ||| S:1247 E:1249 ||| .
In  ||| S:1249 E:1252 ||| IN
contrast ||| S:1252 E:1260 ||| NN
,  ||| S:1260 E:1262 ||| ,
within  ||| S:1262 E:1269 ||| IN
the  ||| S:1269 E:1273 ||| DT
timeframe  ||| S:1273 E:1283 ||| NN
of  ||| S:1283 E:1286 ||| IN
a  ||| S:1286 E:1288 ||| DT
perioperative  ||| S:1288 E:1302 ||| JJ
administration ||| S:1302 E:1316 ||| NN
,  ||| S:1316 E:1318 ||| ,
direct  ||| S:1318 E:1325 ||| JJ
O2  ||| S:1325 E:1328 ||| NN
toxicity  ||| S:1328 E:1337 ||| VBZ
only  ||| S:1337 E:1342 ||| RB
plays  ||| S:1342 E:1348 ||| VBZ
a  ||| S:1348 E:1350 ||| DT
negligible  ||| S:1350 E:1361 ||| JJ
role ||| S:1361 E:1365 ||| NN
.  ||| S:1365 E:1367 ||| .
Pure  ||| S:1367 E:1372 ||| JJ
O2  ||| S:1372 E:1375 ||| CD
ventilation  ||| S:1375 E:1387 ||| NN
induces  ||| S:1387 E:1395 ||| VBZ
peripheral  ||| S:1395 E:1406 ||| JJ
vasoconstriction  ||| S:1406 E:1423 ||| NN
and  ||| S:1423 E:1427 ||| CC
thus  ||| S:1427 E:1432 ||| RB
may  ||| S:1432 E:1436 ||| MD
counteract  ||| S:1436 E:1447 ||| VB
shock-induced  ||| S:1447 E:1461 ||| JJ
hypotension  ||| S:1461 E:1473 ||| NN
and  ||| S:1473 E:1477 ||| CC
reduce  ||| S:1477 E:1484 ||| VB
vasopressor  ||| S:1484 E:1496 ||| JJ
requirements ||| S:1496 E:1508 ||| NNS
.  ||| S:1508 E:1510 ||| .
Furthermore ||| S:1510 E:1521 ||| RB
,  ||| S:1521 E:1523 ||| ,
in  ||| S:1523 E:1526 ||| IN
experimental  ||| S:1526 E:1539 ||| JJ
animals ||| S:1539 E:1546 ||| NNS
,  ||| S:1546 E:1548 ||| ,
a  ||| S:1548 E:1550 ||| DT
redistribution  ||| S:1550 E:1565 ||| NN
of  ||| S:1565 E:1568 ||| IN
cardiac  ||| S:1568 E:1576 ||| JJ
output  ||| S:1576 E:1583 ||| NN
toward  ||| S:1583 E:1590 ||| IN
the  ||| S:1590 E:1594 ||| DT
kidney  ||| S:1594 E:1601 ||| NN
and  ||| S:1601 E:1605 ||| CC
the  ||| S:1605 E:1609 ||| DT
hepato-splanchnic  ||| S:1609 E:1627 ||| JJ
organs  ||| S:1627 E:1634 ||| NNS
was  ||| S:1634 E:1638 ||| VBD
observed ||| S:1638 E:1646 ||| VBN
.  ||| S:1646 E:1648 ||| .
Hyperoxia  ||| S:1648 E:1658 ||| NNP
not  ||| S:1658 E:1662 ||| RB
only  ||| S:1662 E:1667 ||| RB
reverses  ||| S:1667 E:1676 ||| VBZ
the  ||| S:1676 E:1680 ||| DT
anesthesia-related  ||| S:1680 E:1699 ||| JJ
impairment  ||| S:1699 E:1710 ||| NN
of  ||| S:1710 E:1713 ||| IN
the  ||| S:1713 E:1717 ||| DT
host  ||| S:1717 E:1722 ||| NN
defense  ||| S:1722 E:1730 ||| NN
but  ||| S:1730 E:1734 ||| CC
also  ||| S:1734 E:1739 ||| RB
is  ||| S:1739 E:1742 ||| VBZ
an  ||| S:1742 E:1745 ||| DT
antibiotic ||| S:1745 E:1755 ||| NN
.  ||| S:1755 E:1757 ||| .
In  ||| S:1757 E:1760 ||| IN
fact ||| S:1760 E:1764 ||| NN
,  ||| S:1764 E:1766 ||| ,
perioperative  ||| S:1766 E:1780 ||| JJ
hyperoxia  ||| S:1780 E:1790 ||| NNS
significantly  ||| S:1790 E:1804 ||| RB
reduced  ||| S:1804 E:1812 ||| VBN
wound  ||| S:1812 E:1818 ||| JJ
infections ||| S:1818 E:1828 ||| NNS
,  ||| S:1828 E:1830 ||| ,
and  ||| S:1830 E:1834 ||| CC
this  ||| S:1834 E:1839 ||| DT
effect  ||| S:1839 E:1846 ||| NN
was  ||| S:1846 E:1850 ||| VBD
directly  ||| S:1850 E:1859 ||| RB
related  ||| S:1859 E:1867 ||| VBN
to  ||| S:1867 E:1870 ||| TO
the  ||| S:1870 E:1874 ||| DT
tissue  ||| S:1874 E:1881 ||| NN
O2  ||| S:1881 E:1884 ||| CD
tension ||| S:1884 E:1891 ||| NN
.  ||| S:1891 E:1893 ||| .
Therefore ||| S:1893 E:1902 ||| RB
,  ||| S:1902 E:1904 ||| ,
we  ||| S:1904 E:1907 ||| PRP
advocate  ||| S:1907 E:1916 ||| VBP
mechanical  ||| S:1916 E:1927 ||| JJ
ventilation  ||| S:1927 E:1939 ||| NN
with  ||| S:1939 E:1944 ||| IN
100 ||| S:1944 E:1947 ||| CD
%  ||| S:1947 E:1949 ||| NN
O2  ||| S:1949 E:1952 ||| NN
during  ||| S:1952 E:1959 ||| IN
the  ||| S:1959 E:1963 ||| DT
first  ||| S:1963 E:1969 ||| JJ
12  ||| S:1969 E:1972 ||| CD
to  ||| S:1972 E:1975 ||| TO
24  ||| S:1975 E:1978 ||| CD
hrs  ||| S:1978 E:1982 ||| NN
of  ||| S:1982 E:1985 ||| IN
septic  ||| S:1985 E:1992 ||| JJ
shock ||| S:1992 E:1997 ||| NN
.  ||| S:1997 E:1999 ||| .
However ||| S:1999 E:2006 ||| RB
,  ||| S:2006 E:2008 ||| ,
controlled  ||| S:2008 E:2019 ||| VBN
clinical  ||| S:2019 E:2028 ||| JJ
trials  ||| S:2028 E:2035 ||| NNS
are  ||| S:2035 E:2039 ||| VBP
mandatory  ||| S:2039 E:2049 ||| JJ
to  ||| S:2049 E:2052 ||| TO
test  ||| S:2052 E:2057 ||| VB
the  ||| S:2057 E:2061 ||| DT
safety  ||| S:2061 E:2068 ||| NN
and  ||| S:2068 E:2072 ||| CC
efficacy  ||| S:2072 E:2081 ||| NN
of  ||| S:2081 E:2084 ||| IN
this  ||| S:2084 E:2089 ||| DT
approach ||| S:2089 E:2097 ||| NN
.  ||| S:2097 E:2099 ||| .
